QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorOdense University Hospital
About this trial
The goal of this observational study is to see how type 2 diabetes affects quality of life in cancer patients receiving immunotherapy. We want to know if patients with diabetes have a greater decline in quality of life over six months compared to those without. The main question we aim to answer is:
\- How does quality of life change over six months in patients with versus without diabetes?
Participants will complete quality-of-life surveys at the start, then at 3 and 6 months. This will help us see if diabetes adds extra challenges during cancer treatment
Eligibility criteria
Qualifiers
Age ≥18 years.
Histologically confirmed solid malignant tumor.
Planned treatment with ICI monotherapy or dual-ICI combination therapy (metastatic, adjuvant, or neo-adjuvant settings).
Previous systemic anticancer therapy other than ICI is allowed.
Disqualifiers
Previous ICI treatment within 6 months.
Concurrent systemic anticancer therapy other than ICI.
Declines or does not provide informed consent.
Cognitive or physical impairment preventing valid consent or completion of patient-reported outcomes.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
920 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov